Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others
Bioseeker, January 2012, Pages: 1704
This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.
A large number of drugs, both on the market and in development have angiogenesis affecting properties. This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).
This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.
- Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.
- The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.
- Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.
- Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.
- Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer.
- The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.
- The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.
1 Executive Summary
2 About Cancer Highlights™
2.1 Cancer Focus Areas
2.2 Subscribe Today and Start Saving
2.2.1 Type of License
2.3 Additional Information
2.4 BioSeeker Group’s Oncology Team
3 Methodology
3.1 Cancer Highlights’™ Five Pillar Drug Assessment
4 Table of Contents
4.1 List of Figures
4.2 List of Tables
5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment
6.1 Drug Repositioning in Oncology
6.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology
6.2.1 Calcium Ion Binding Targets
6.2.2 Carboxy-lyase Activity Targets
6.2.3 Catalytic Activity Targets
6.2.4 Cell Adhesion Molecule Activity Targets
6.2.5 Chaperone Activity Targets
6.2.6 Chemokine Activity Targets
6.2.7 Cofactor Binding Targets
6.2.8 Cysteine-type Peptidase Activity Targets
6.2.9 Cytokine Activity Targets
6.2.10 Cytoskeletal Protein Binding Targets
6.2.11 DNA Topoisomerase Activity Targets
6.2.12 DNA-directed DNA Polymerase Activity Targets
6.2.13 Extracellular Matrix Structural Constituent Targets
6.2.14 G-protein Coupled Receptor Activity Targets
6.2.15 Growth Factor Activity Targets
6.2.16 GTPase Activity Targets
6.2.17 Hormone Activity Targets
6.2.18 Hydrolase Activity Targets
6.2.19 Kinase Activity Targets
6.2.20 Kinase Binding Targets
6.2.21 Lipid Kinase Activity Targets
6.2.22 Metallopeptidase Activity Targets
6.2.23 Molecular Function Unknown Targets
6.2.24 Motor Activity Targets
6.2.25 Oxidoreductase Activity Targets
6.2.26 Peptidase Activity Targets
6.2.27 Phosphoric Diester Hydrolase Activity Targets
6.2.28 Protease Inhibitor Activity Targets
6.2.29 Protein Binding Targets
6.2.30 Protein Serine/Threonine Kinase Activity Targets
6.2.31 Protein-tyrosine Kinase Activity Targets
6.2.32 Receptor Activity Targets
6.2.33 Receptor Binding Targets
6.2.34 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets
6.2.35 RNA Binding Targets
6.2.36 Serine-type Peptidase Activity Targets
6.2.37 Structural Constituent of Cytoskeleton Targets
6.2.38 Superoxide Dismutase Activity Targets
6.2.39 Transcription Factor Activity Targets
6.2.40 Transcription Regulator Activity Targets
6.2.41 Transferase Activity Targets
6.2.42 Translation Regulator Activity Targets
6.2.43 Transmembrane Receptor Activity Targets
6.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.45 Transporter Activity Targets
6.2.46 Ubiquitin-specific Protease Activity Targets
6.2.47 Unknown Function Targets
6.2.48 Voltage-gated Ion Channel Activity Targets
6.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology
6.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets
6.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology
6.6 The Drug-Target Competitive Landscape
6.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology
6.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology
6.8.1 Tools for Analysis of Cancer Pathways
6.8.2 Pathway Assessment
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology
7.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology
7.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology
7.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology
7.7.1 Marketed
7.7.2 Pre-registration
7.7.3 Phase III
7.7.4 Phase II
7.7.5 Phase I
7.7.6 Preclinical
7.7.7 Suspended
7.7.8 Ceased
7.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy
8.1 Small Molecules
8.1.1 Background
8.1.2 Target Strategies of Small Molecule Drugs
8.2 Peptide & Protein Drugs
8.2.1 Background
8.2.2 Target Strategies of Peptide and Protein Drugs
8.3 Antibodies
8.3.1 Background
8.3.2 Target Strategies of Antibody Drugs
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Target Strategies of Nucleic Acid Drugs
8.5 Gene Therapy
8.5.1 Background
8.5.2 Target Strategies of Gene Therapy Drugs
8.6 Drug Delivery and Nanotechnology
8.6.1 Background
8.6.2 Target Strategies of Reformulated Drugs
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology
9.1 Acute Lymphocytic Leukemia
9.2 Acute Myelogenous Leukemia
9.3 Adrenal Cancer
9.4 B-cell Lymphoma
9.5 Basal Cell Cancer
9.6 Biliary Cancer
9.7 Bladder Cancer
9.8 Bone Cancer
9.9 Brain Cancer
9.10 Breast Cancer
9.11 Cancer (general)
9.12 Carcinoid
9.13 Cervical Cancer
9.14 Chemopreventative
9.15 Chronic Lymphocytic Leukemia
9.16 Chronic Myelogenous Leukemia
9.17 Chronic Myelomonocytic Leukemia
9.18 CNS Cancer
9.19 Colorectal Cancer
9.20 Endometrial Cancer
9.21 Fallopian Tube Cancer
9.22 Fibro Sarcoma
9.23 Gastrointestinal Cancer (general)
9.24 Gastrointestinal Stomach Cancer
9.25 Gastrointestinal Stromal Cancer
9.26 Head and Neck Cancer
9.27 Hematological Cancer (general)
9.28 Hodgkin's Lymphoma
9.29 Kaposi's Sarcoma
9.30 Leiomyo Sarcoma
9.31 Leukemia (general)
9.32 Lipo Sarcoma
9.33 Liver Cancer
9.34 Lung Cancer (general)
9.35 Lymphangioleiomyomatosis
9.36 Lymphoma (general)
9.37 Mast Cell Leukemia
9.38 Mastocytosis
9.39 Melanoma
9.40 Mesothelioma
9.41 Myelodysplastic Syndrome
9.42 Myeloma
9.43 Nasopharyngeal Cancer
9.44 Neuroendocrine Cancer (general)
9.45 Neuroendocrine Cancer (pancreatic)
9.46 Neurofibromatosis
9.47 non-Hodgkin's Lymphoma
9.48 Non-Small Cell Lung Cancer
9.49 Oesophageal Cancer
9.50 Oral Cancer
9.51 Osteo Sarcoma
9.52 Ovarian Cancer
9.53 Pancreatic Cancer
9.54 Peritoneal Cancer
9.55 Prostate Cancer
9.56 Radio/chemotherapy-induced Alopecia
9.57 Radio/chemotherapy-induced Infection
9.58 Renal Cancer
9.59 Sarcoma (general)
9.60 Small Cell Lung Cancer
9.61 Soft Tissue Sarcoma
9.62 Solid Tumor
9.63 Squamous Cell Cancer
9.64 Synovial Sarcoma
9.65 T-cell Lymphoma
9.66 Testicular Cancer
9.67 Thyroid Cancer
9.68 Unspecified
9.69 Vaccine adjunct
9.70 Waldenstrom's hypergammaglobulinemia
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator
10.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
10.2 Company Facts and Ranking
10.3 Competitive Fall-Out Assessment
10.4 Abbott
10.5 Acceleron Pharma
10.6 Access
10.7 Active Biotech
10.8 Adherex
10.9 Advantagene
10.10 Advaxis
10.11 Advenchen
10.12 AEterna Zentaris
10.13 Agennix
10.14 Aida Pharmaceuticals
10.15 Alnylam
10.16 Ambit Biosciences
10.17 Ambrilia Biopharma
10.18 Amgen
10.19 Amphora
10.20 Angiogen
10.21 Angiogenex
10.22 Angstrom Pharmaceuticals
10.23 Ansaris
10.24 Antisoma
10.25 Arana Therapeutics
10.26 Ariad
10.27 Arno Therapeutics
10.28 ArQule
10.29 Array BioPharma
10.30 Astellas
10.31 Astex Therapeutics
10.32 AstraZeneca
10.33 Attenuon
10.34 Austrianova
10.35 Bayer
10.36 BioAlliance Pharma
10.37 BioAxone
10.38 Biocad
10.39 Boehringer Ingelheim
10.40 Bolder BioTechnology
10.41 Bristol-Myers Squibb
10.42 BTG
10.43 Cancer Research Technology
10.44 CDG Therapeutics
10.45 Celecure
10.46 Celera
10.47 Celgene
10.48 Cell Therapeutics
10.49 CellCeutix
10.50 Cellmid
10.51 Cephalon
10.52 ChemoCentryx
10.53 Chemokine Therapeutics
10.54 China Sky One Medical
10.55 Choongwae
10.56 Circadian Technologies
10.57 Cue Biotech
10.58 Curis
10.59 Cyclacel
10.60 Cytochroma
10.61 Deciphera Pharmaceuticals
10.62 Dendreon
10.63 Dyax
10.64 Eisai
10.65 Eli Lilly
10.66 EntreMed
10.67 Exelixis
10.68 ExonHit Therapeutics
10.69 Five Prime Therapeutics
10.70 GammaCan
10.71 Genmab
10.72 Gilead Sciences
10.73 GlaxoSmithKline
10.74 GlycoGenesys
10.75 Green Cross
10.76 Hoffmann-La Roche
10.77 Hy BioPharma
10.78 Idera Pharmaceuticals
10.79 ImClone Systems
10.80 ImmunoGen
10.81 ImmuPharma
10.82 Introgen Therapeutics
10.83 Isis Pharmaceuticals
10.84 Johnson & Johnson
10.85 KAI Pharmaceuticals
10.86 Karus Therapeutics
10.87 Kirin Pharma
10.88 Kringle Pharma
10.89 Kyowa Hakko Kirin
10.90 Lee's Pharmaceutical
10.91 Lorus Therapeutics
10.92 MAT Biopharma
10.93 MediGene
10.94 Merck & Co
10.95 Merck KGaA
10.96 Mersana Therapeutics
10.97 MethylGene
10.98 Micromet
10.99 MolMed
10.100 Morvus Technology
10.101 NewSouth Innovations
10.102 Non-industrial Source
10.103 Novartis
10.104 Novelix
10.105 Noxxon
10.106 Oasmia
10.107 Onconova
10.108 OncoTherapy Science
10.109 Oncothyreon
10.110 OSI Pharmaceuticals
10.111 Oxford BioMedica
10.112 OXiGENE
10.113 Pepscan Therapeutics
10.114 PepTx
10.115 Peregrine Pharmaceuticals
10.116 Pfizer
10.117 Pharmacopeia
10.118 PharmaMar
10.119 Pharminox
10.120 Philogen
10.121 PhiloGene
10.122 Pierre Fabre
10.123 Progen
10.124 Protein Sciences
10.125 Protgen
10.126 PTC Therapeutics
10.127 Receptor BioLogix
10.128 Regeneron
10.129 Rexahn
10.130 Rigel
10.131 Sanofi
10.132 Santaris Pharma
10.133 Scancell
10.134 SciClone Pharmaceuticals
10.135 Semafore Pharmaceuticals
10.136 Shionogi
10.137 Simcere Pharmaceuticals
10.138 Spear Therapeutics
10.139 SRI International
10.140 Stainwei Biotech
10.141 SuperGen
10.142 Switch Pharma
10.143 SynDevRx
10.144 Taiho
10.145 Tau Therapeutics
10.146 ThromboGenics
10.147 Tigris Pharmaceuticals
10.148 ToolGen
10.149 TopoTarget
10.150 Tracon Pharmaceuticals
10.151 UCB
10.152 VBL Therapeutics
10.153 Wilex
10.154 Xerion
11 Disclaimer
12 Drug Index
13 Company Index
4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology
Figure 2: The Drug-Target Competitive Landscape of Angiogenesis Affecting Drugs in Oncology - Large Cluster
Figure 3: The Drug-Target Competitive Landscape Angiogenesis Affecting Drugs in Oncology - Smaller Clusters
Figure 4: Head-to-Head Targeting Competitive Landscape of Angiogenesis Affecting Drugs in Oncology
Figure 5: Distribution of Compound Strategies among Angiogenesis Affecting Cancer Drugs
Figure 6: Primary Sub-cellular Localization of Drug Targets
Figure 7: Number of Companies per Ranking Level
4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment
Table 2: Breakdown of the Included Angiogenesis Affecting Drug Pipeline in Oncology by Stage of Development
Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Oncology
Table 4: Overview of Drug Target Strategy Themes
Table 5: Terminally Ceased Targets of Angiogenesis Affecting Drugs in Oncology
Table 6: Official Gene Name to Target Profle
Table 7: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 8: Identity of Drug Targets with Available Biological Structures
Table 9: Number of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology
Table 10: Available Protein Expression Profiles of Angiogenesis Affecting Drug Targets in Oncology
Table 11: Pathway Summary
Table 12: Drug Targets without any Identified Assigned Pathways
Table 13: Pathway Profiles According to BioCarta of Angiogenesis Affecting Drug Targets in Oncology
Table 14: Pathway Profiles According to KEGG of Angiogenesis Affecting Drug Targets in Oncology
Table 15: Pathway Profiles According to NetPath of Angiogenesis Affecting Drug Targets in Oncology
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
Table 17: Top Competitive Target Strategies of Angiogenesis Affecting Drugs in Oncology
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Angiogenesis Affecting Drugs in Oncology
Table 19: The Competition Through Close Mechanistic Approximation Between Angiogenesis Affecting Drugs in Oncology in Pre-registration to Marketed
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Angiogenesis Affecting Drugs in Oncology
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Angiogenesis Affecting Drugs in Oncology
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Angiogenesis Affecting Drugs in Oncology
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Angiogenesis Affecting Drugs in Oncology
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Angiogenesis Affecting Drugs in Oncology
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Angiogenesis Affecting Drugs in Oncology
Table 26: New and Unique Target Strategies in Preclinical Development of Angiogenesis Affecting Drugs in Oncology
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Angiogenesis Affecting Drugs in Oncology
Table 28: Target Strategies of No Data, Suspended and Terminated Angiogenesis Affecting Drugs in Oncology
Table 29: Connecting Target Strategy with Its Profile Identification Number
Table 30: The Competition Through Close Mechanistic Approximation Among Angiogenesis Affecting Drugs in Oncology
Table 31: Overview of Compound Strategy Competition Among Angiogenesis Affecting Cancer Drugs
Table 32: Overview of the Competitive Landscape of Small Molecule Based Angiogenesis Affecting Cancer Drugs
Table 33: Competitive Comparison of Target Strategies of Small Molecule Angiogenesis Affecting Cancer Drugs
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Angiogenesis Affecting Cancer Drugs
Table 35: Overview of the Competitive Landscape of Peptide Based Angiogenesis Affecting Cancer Drugs
Table 36: Competitive Comparison of Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs
Table 37: Pursued Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs
Table 38: Overview of the Competitive Landscape of Protein Based Angiogenesis Affecting Cancer Drugs
Table 39: Competitive Comparison of Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs
Table 40: Pursued Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs
Table 41: Overview of the Competitive Landscape of Antibody Based Angiogenesis Affecting Cancer Drugs
Table 42: Competitive Comparison of Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs
Table 43: Pursued Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs
Table 46: Pursued Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs
Table 47: Vectors in Gene Therapy
Table 48: Overview of the Competitive Landscape of Gene Therapy Based Angiogenesis Affecting Cancer Drugs
Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs
Table 50: Pursued Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs
Table 51:Overview of the Competitive Landscape of Reformulated Angiogenesis Affecting Cancer Drugs
Table 52: Competitive Comparison of Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs
Table 53: Pursued Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs
Table 54: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Cancer Drug Targets
Table 55 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs
Table 56: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia
Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia
Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs
Table 59: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer
Table 60: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs
Table 61: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma
Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer
Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer
Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer
Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs
Table 66: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer
Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer
Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs
Table 69: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer
Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs
Table 71: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general)
Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid
Table 73: The Competition through Close Mechanistic Approximation between Carcinoid Drugs
Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer
Table 75: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemopreventative
Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia
Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia
Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelomonocytic Leukemia
Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer
Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer
Table 81: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs
Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer
Table 83: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs
Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer
Table 85: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs
Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma
Table 87: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general)
Table 88: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs
Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer
Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs
Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer
Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs
Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer
Table 94: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs
Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hematological Cancer (general)
Table 96: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma
Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma
Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma
Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general)
Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma
Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer
Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs
Table 103: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general)
Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphangioleiomyomatosis
Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general)
Table 106: The Competition through Close Mechanistic Approximation between Lymphoma Drugs
Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia
Table 108: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mastocytosis
Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma
Table 110: The Competition through Close Mechanistic Approximation between Melanoma Drugs
Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma
Table 112: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs
Table 113: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome
Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma
Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs
Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer
Table 117: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general)
Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic)
Table 119: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs
Table 120: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neurofibromatosis
Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma
Table 122: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs
Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer
Table 124: The Competition through Close Mechanistic Approximation between non-Small Cell Lung Cancer Drugs
Table 125: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer
Table 126: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs
Table 127: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer
Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma
Table 129: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer
Table 130: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs
Table 131: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer
Table 132: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs
Table 133: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer
Table 134: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs
Table 135: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer
Table 136: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs
Table 137: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Alopecia
Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Infection
Table 139: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer
Table 140: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs
Table 141: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general)
Table 142: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs
Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer
Table 144: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs
Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma
Table 146: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs
Table 147: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor
Table 148: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs
Table 149: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer
Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma
Table 151: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma
Table 152: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer
Table 153: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer
Table 154: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified
Table 155: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct
Table 156: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia
Table 157: Competitive Summary by Investigator of Angiogenesis Affecting Drug Development
Table 158: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology
Table 159: Example of a Competitive Fall-Out Table (Targeting KDR/Modified)
Table 160: Abbott's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 161: Acceleron Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 162: Access’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 163: Active Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 164: Adherex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 165: Advantagene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 166: Advaxis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 167: Advenchen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 168: AEterna Zentaris’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 169: Agennix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 170: Aida Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 171: Alnylam's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 172: Ambit Biosciences’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 173: Ambrilia Biopharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 174: Amgen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 175: Amphora's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 176: Angiogen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 177: Angiogenex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 178: Angstrom Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 179: Ansaris’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 180: Antisoma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 181: Arana Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 182: Ariad's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 183: Arno Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 184: ArQule's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 185: Array BioPharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 186: Astellas’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 187: Astex Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 188: AstraZeneca's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 189: Attenuon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 190: Austrianova's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 191: Bayer's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 192: BioAlliance Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 193: BioAxone's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 194: Biocad's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 195: Boehringer Ingelheim's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 196: Bolder BioTechnology's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 197: Bristol-Myers Squibb's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 198: BTG's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 199: Cancer Research Technology's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 200: CDG Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 201: Celecure's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 202: Celera's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 203: Celgene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 204: Cell Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 205: CellCeutix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 206: Cellmid's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 207: Cephalon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 208: ChemoCentryx's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 209: Chemokine Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 210: China Sky One Medical's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 211: Choongwae's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 212: Circadian Technologies’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 213: Cue Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 214: Curis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 215: Cyclacel's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 216: Cytochroma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 217: Deciphera Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 218: Dendreon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 219: Dyax's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 220: Eisai's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 221: Eli Lilly's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 222: EntreMed's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 223: Exelixis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 224: ExonHit Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 225: Five Prime Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 226: GammaCan's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 227: Genmab's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 228: Gilead Sciences’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 229: GlaxoSmithKline's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 230: GlycoGenesys’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 231: Green Cross’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 232: Hoffmann-La Roche's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 233: Hy BioPharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 234: Idera Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 235: ImClone Systems’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 236: ImmunoGen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 237: ImmuPharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 238: Introgen Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 239: Isis Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 240: Johnson & Johnson's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 241: KAI Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 242: Karus Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 243: Kirin Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 244: Kringle Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 245: Kyowa Hakko Kirin's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 246: Lee's Pharmaceutical's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 247: Lorus Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 248: MAT Biopharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 249: MediGene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 250: Merck & Co's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 251: Merck KGaA's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 252: Mersana Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 253: MethylGene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 254: Micromet's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 255: MolMed's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 256: Morvus Technology's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 257: NewSouth Innovations’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 258: Non-industrial source's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 259: Novartis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 260: Novelix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 261: Noxxon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 262: Oasmia's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 263: Onconova's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 264: OncoTherapy Science's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 265: Oncothyreon's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 266: OSI Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 267: Oxford BioMedica's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 268: OXiGENE's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 269: Pepscan Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 270: PepTx's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 271: Peregrine Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 272: Pfizer's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 273: Pharmacopeia's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 274: PharmaMar's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 275: Pharminox's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 276: Philogen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 277: PhiloGene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 278: Pierre Fabre's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 279: Progen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 280: Protein Sciences’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 281: Protgen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 282: PTC Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 283: Receptor BioLogix's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 284: Regeneron's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 285: Rexahn's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 286: Rigel's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 287: Sanofi's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 288: Santaris Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 289: Scancell's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 290: SciClone Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 291: Semafore Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 292: Shionogi's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 293: Simcere Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 294: Spear Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 295: SRI International's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 296: Stainwei Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 297: SuperGen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 298: Switch Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 299: SynDevRx's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 300: Taiho's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 301: Tau Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 302: ThromboGenics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 303: Tigris Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 304: ToolGen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 305: TopoTarget's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 306: Tracon Pharmaceuticals’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 307: UCB's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 308: VBL Therapeutics’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 309: Wilex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
Table 310: Xerion's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out
- Abbott
- Acceleron Pharma
- Access
- Active Biotech
- Adherex
- Advantagene
- Advaxis
- Advenchen
- AEterna Zentaris
- Agennix
- Aida Pharmaceuticals
- Alnylam
- Ambit Biosciences
- Ambrilia Biopharma
- Amgen
- Amphora
- Angiogen
- Angiogenex
- Angstrom Pharmaceuticals
- Ansaris
- Antisoma
- Arana Therapeutics
- Ariad
- Arno Therapeutics
- ArQule
- Array BioPharma
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- Austrianova
- Bayer
- BioAlliance Pharma
- BioAxone
- Biocad
- Boehringer Ingelheim
- Bolder BioTechnology
- Bristol-Myers Squibb
- BTG
- Cancer Research Technology
- CDG Therapeutics
- Celecure
- Celera
- Celgene
- Cell Therapeutics
- CellCeutix
- Cellmid
- Cephalon
- ChemoCentryx
- Chemokine Therapeutics
- China Sky One Medical
- Choongwae
- Circadian Technologies
- Cue Biotech
- Curis
- Cyclacel
- Cytochroma
- Deciphera Pharmaceuticals
- Dendreon
- Dyax
- Eisai
- Eli Lilly
- EntreMed
- Exelixis
- ExonHit Therapeutics
- Five Prime Therapeutics
- GammaCan
- Genmab
- Gilead Sciences
- GlaxoSmithKline
- GlycoGenesys
- Green Cross
- Hoffmann-La Roche
- Hy BioPharma
- Idera Pharmaceuticals
- ImClone Systems
- ImmunoGen
- ImmuPharma
- Introgen Therapeutics
- Isis Pharmaceuticals
- Johnson & Johnson
- KAI Pharmaceuticals
- Karus Therapeutics
- Kirin Pharma
- Kringle Pharma
- Kyowa Hakko Kirin
- Lee's Pharmaceutical
- Lorus Therapeutics
- MAT Biopharma
- MediGene
- Merck & Co
- Merck KGaA
- Mersana Therapeutics
- MethylGene
- Micromet
- MolMed
- Morvus Technology
- NewSouth Innovations
- Non-industrial Source
- Novartis
- Novelix
- Noxxon
- Oasmia
- Onconova
- OncoTherapy Science
- Oncothyreon
- OSI Pharmaceuticals
- Oxford BioMedica
- OXiGENE
- Pepscan Therapeutics
- PepTx
- Peregrine Pharmaceuticals
- Pfizer
- Pharmacopeia
- PharmaMar
- Pharminox
- Philogen
- PhiloGene
- Pierre Fabre
- Progen
- Protein Sciences
- Protgen
- PTC Therapeutics
- Receptor BioLogix
- Regeneron
- Rexahn
- Rigel
- Sanofi
- Santaris Pharma
- Scancell
- SciClone Pharmaceuticals
- Semafore Pharmaceuticals
- Shionogi
- Simcere Pharmaceuticals
- Spear Therapeutics
- SRI International
- Stainwei Biotech
- SuperGen
- Switch Pharma
- SynDevRx
- Taiho
- Tau Therapeutics
- ThromboGenics
- Tigris Pharmaceuticals
- ToolGen
- TopoTarget
- Tracon Pharmaceuticals
- UCB
- VBL Therapeutics
- Wilex
- Xerion
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW6
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
